Minhee Kang

Biography

Dr. Minhee Kang is a Senior Research Scientist at the Center for Biostatistics in AIDS Research (CBAR) in the Department of Biostatistics at Harvard T.H. Chan School of Public Health. She has led statistical efforts for over 20 therapeutic and vaccine clinical trials and observational studies in infectious diseases. They range from dose-finding Phase I and test-of concept Phase I/II trials to Phase III confirmatory trials in HIV, human papillomavirus (HPV), Kaposi sarcoma-associated herpesvirus (KSHV), and hepatitis B and C (HBV, HCV).

She collaborates in the NIAID-funded ACTG (Advancing Clinical Therapeutics Globally) clinical trials network and serves on the Hepatitis Steering Committee to plan scientific and implementation strategies for promoting hepatitis clinical trials. She also serves on an independent ACTG Study Monitoring Committee for periodical reviews of the accumulating interim data to monitor safety, efficacy, and conduct of clinical trials aimed at HIV viral eradication and cure.

Dr. Kang has contributed to the statistical research in multi-state models, including their applications to assess imperfect, operational definitions of persistent infection in HPV and HCV. Her recent contributions are in efficient and practical clinical trial designs motivated by her collaborations in the ACTG.

Education and Training

• Ph.D., Biostatistics
  Harvard University
• Sc.B., Applied Mathematics
  Brown University
• M.S., Operations Research
  Cornell University

Awards and Honors

• Howard Hughes Medical Institute Predoctoral Fellowship in Biological Sciences, 1998 - 2003

Publications

• An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.

  Kang M, Marks KM, Cox AL, Sherman KE. Vaccine 2025 May 10

  PMID: 40147293

• HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial.

  Marks KM, Kang M, Umbleja T, Cox A, Vigil KJ, Ta NT, Omoz-Oarhe A, Perazzo H, Kosgei J, Hatlen T, Price J, Katsidzira L, Supparatpinyo K, Knowles K, Alston-Smith BL, Rathod P, Sherman KE. JAMA 2025 01 28

  PMID: 39616603

• Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067.

  Chagomerana MB, Moser CB, Kang M, Umbleja T, Hughes MD, Campbell TB, Krown SE, Borok MZ, Samaneka W, Ngongondo M, Nyirenda M, Langat DC, Hoagland B, Burger H, Busakhala N, Njiru E, Mwelase N, Mngqibisa R, Hosseinipour MC. J Acquir Immune Defic Syndr 2024 Nov 01

  PMID: 39431505

• Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings.

  Epeldegui M, Chang D, Lee J, Magpantay LI, Borok M, Bukuru A, Busakhala N, Godfrey C, Hosseinipour MC, Kang M, Kanyama C, Langat D, Mngqibisa R, Mwelase N, Nyirenda M, Samaneka W, Hoagland B, Campbell TB, Martínez-Maza O, Krown SE. J Acquir Immune Defic Syndr 2023 10 01

  PMID: 37368929

• Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV.

  Kang M, Price JC, Peters MG, Lewin SR, Sulkowski M. J Virus Erad 2023

  PMID: 37744732